This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (47)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Time for Change

Jack Hirsh, MD

Arch Intern Med. 1992;152(2):257-258.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Warfarin is a very effective antithrombotic drug, but its dosage must be monitored carefully because its metabolic clearance varies among patients and the risk of clinically important bleeding rises sharply when the upper limit of the effective range is exceeded.

Warfarin therapy is usually monitored by the prothrombin time (PT).¹ The PT is sensitive to three of the four vitamin K-dependent procoagulant clotting factors and is obtained by adding a mixture of calcium and thromboplastin to citrated plasma. The term thromboplastin describes a phospholipid-protein extract of tissues, usually lung, brain, or placenta, that contains both the tissue factor and the phospholipid necessary to promote the activation of factor X by factor VII.^1,2 The PT is a simple test, but its interpretation can be problematic because thromboplastins vary markedly in their responsiveness to the anticoagulant effects of warfarin depending on their source and method of preparation.^3-9 As a . . . [Full Text PDF of this Article]

Author Affiliations
Hamilton Civic Hospitals Research Center 711 Concession St Hamilton, Ontario, Canada L8V 1C33

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?